Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide.
Marco Cavaco,Marco Cavaco,Patrícia Fraga,Javier Valle,David Andreu,Miguel A. R. B. Castanho,Vera Neves +6 more
Reads0
Chats0
TLDR
In this article, the authors explored the development and characterization of three-dimensional (3D) models, named spheroids, of the most aggressive breast cancer subtypes (triple negative breast cancer-TNBC; and human-epidermal growth receptor-2-HER2+), using the liquid overlay technique with several selected cell lines.Abstract:
Breast cancer (BC) is the most commonly diagnosed cancer in women and one of the most common causes of cancer-related deaths. Despite intense research efforts, BC treatment still remains challenging. Improved drug development strategies are needed for impactful benefit to patients. Current preclinical studies rely mostly on cell-based screenings, using two-dimensional (2D) cell monolayers that do not mimic in vivo tumors properly. Herein, we explored the development and characterization of three-dimensional (3D) models, named spheroids, of the most aggressive BC subtypes (triple-negative breast cancer-TNBC; and human-epidermal growth receptor-2-HER2+), using the liquid overlay technique with several selected cell lines. In these cell line-derived spheroids, we studied cell density, proliferation, ultrastructure, apoptosis, reactive oxygen species (ROS) production, and cell permeabilization (live/dead). The results showed a formation of compact and homogeneous spheroids on day 7 after seeding 2000 cells/well for MDA-MB-231 and 5000 cells/well for BT-20 and BT-474. Next, we compared the efficacy of a model anticancer peptide (ACP) in cell monolayers and spheroids. Overall, the results demonstrated spheroids to be less sensitive to treatment than cell monolayers, revealing the need for more robust models in drug development.read more
Citations
More filters
Journal ArticleDOI
Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment
TL;DR: In this article , a review of 3D in vitro cancer models for the efficacy evaluation of anticancer agents is presented, focusing on their potential contribution to replace, reduce and refine animal experimentations, highlighting their strength and weakness, and discussing possible perspectives to overcome current challenges.
Journal ArticleDOI
Three-Dimensional in Vitro Models: A Promising Tool To Scale-Up Breast Cancer Research.
Vajihe Azimian Zavareh,Laleh Rafiee,Mohammad Reza Zadeh Sheikholeslam,Laleh Shariati,Golnaz Vaseghi,Houman Savoji,Shaghayegh Haghjooy Javanmard +6 more
TL;DR: This review attempts to summarize the most common 3D in vitro models used in breast cancer studies, including scaffold-free (spheroid and organoid), scaffolding-based, and chip-based models, particularly focused on the basic and translational application of these 3D models in drug screening and the tumor microenvironment in Breast cancer.
Journal ArticleDOI
Trimethoxy trityl groups as a potent substituent for anti-cancer cytidine analog prodrugs.
Chihiro Ito,Kazuaki Taguchi,Yoshie Moroi,Yuki Enoki,Ryoh Tokuda,Keishi Yamasaki,Shuhei Imoto,Kazuaki Matsumoto +7 more
TL;DR: In this paper , the potential of methoxy trityl groups, monomethoxy triityl (MMT), dimethoxy triethyltyll (DMT), and trimethoxy trithl (TMT) as acid-responsive substituents for designing anti-cancer cytidine analog prodrugs was investigated.
Journal ArticleDOI
Tumor Organoid and Spheroid Models for Cervical Cancer
TL;DR: A comprehensive overview of the currently available 3D (3D) models of cervical cancer and their significance in pre-clinical and clinical studies is provided in this paper , where the authors emphasize the potential of 3D tumor models, such as spheroids from cervical cancer cell lines and patient-derived organoids, to evaluate novel therapies, particularly immunotherapies that target tumor cells and modulate the tumor microenvironment.
Journal ArticleDOI
Gradient Retention Factor Concept Applied to Method Development for Peptide Analysis by Means of RP-HPLC
Nicolás Mateo González-López,Diego Sebastián Insuasty-Cepeda,Kevin Andrey Huertas‐Ortiz,Juan Esteban Reyes-Calderón,Jorge A. Martínez-Ramírez,Ricardo Fierro-Medina,Zuly Jenny Rivera-Monroy,Javier Eduardo García-Castañeda +7 more
TL;DR: Using the van Deemter model, the efficiency of three stationary phase systems in the analysis of a mixture of synthetic peptides was evaluated: (i) monolithic, (ii) packed, and (iii) core-shell columns, and it was shown that the monolithic column is superior to the others, specifically using it, and additionally its efficiency was not significantly affected by increasing the flow as discussed by the authors .
References
More filters
Journal ArticleDOI
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine Piccart-Gebhart,Marion Procter,Brian Leyland-Jones,Aron Goldhirsch,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Richard Bell,Christian Jackisch,David Cameron,Mitch Dowsett,Carlos H. Barrios,Günther G. Steger,Chiun-Shen Huang,Martin Andersson,Moshe Inbar,Mikhail Lichinitser,István Láng,U. Nitz,Hiroji Iwata,C Thomssen,Caroline Lohrisch,Thomas M. Suter,Josef Rüschoff,Tamás Süto ý,Victoria Greatorex,Carol Ward,Eleanor McFadden,M. Stella Dolci,Richard D. Gelber +30 more
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond,Daniel F. Hayes,Mitch Dowsett,D. Craig Allred,Karen L. Hagerty,Sunil V. Badve,Patrick L. Fitzgibbons,Glenn Francis,Neil S. Goldstein,Malcolm Hayes,David G. Hicks,Susan C. Lester,Richard Love,Pamela B. Mangu,Lisa M. McShane,Keith Miller,C. Kent Osborne,Soonmyung Paik,Jane Perlmutter,Anthony Rhodes,Hironobu Sasano,Jared N. Schwartz,Fred C.G.J. Sweep,Sheila E. Taube,Emina Torlakovic,Paul N. Valenstein,Giuseppe Viale,Daniel W. Visscher,Thomas M. Wheeler,R. Bruce Williams,James L. Wittliff,Antonio C. Wolff +31 more
TL;DR: An international Expert Panel that conducted a systematic review and evaluation of the literature and developed recommendations for optimal IHC ER/PgR testing performance recommended that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences.
Journal ArticleDOI
Triple-negative breast cancer.
TL;DR: Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer.
Journal ArticleDOI
Network pharmacology: the next paradigm in drug discovery.
TL;DR: A new appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development--efficacy and toxicity.
Journal ArticleDOI
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff,M. Elizabeth H. Hammond,David G. Hicks,Mitch Dowsett,Lisa M. McShane,Kimberly H. Allison,D. C. Allred,John M. S. Bartlett,Michael Bilous,Patrick L. Fitzgibbons,Wedad Hanna,Robert B. Jenkins,Pamela B. Mangu,Soonmyung Paik,Edith A. Perez,Michael F. Press,Patricia A. Spears,Gail H. Vance,Giuseppe Viale,Daniel F. Hayes +19 more
TL;DR: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive).